Shukra Pharmaceuticals Ltd
BSE: 524632
Revenue & Profit Trend
in croresMargin Trend
percentage| Period | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|---|
| INCOME | ||||||||
| Revenue | 23.52+273.2% | 6.30-83.9% | 39.13+565.9% | 5.88+9.0% | 5.39-59.4% | 13.27+25.4% | 10.58+90.5% | 5.55 |
| Other Income | 0.54-43.0% | 0.95+16.2% | 0.82-52.4% | 1.71+54.3% | 1.11-24.3% | 1.47+45.7% | 1.01-1.1% | 1.02 |
| Total Income | 24.06+231.9% | 7.25-81.9% | 39.95+426.4% | 7.59+16.8% | 6.50-55.9% | 14.74+27.1% | 11.59+76.3% | 6.57 |
| EXPENSES | ||||||||
| Expenditure | 3.82-44.5% | 6.88-47.5% | 13.12+77.5% | 7.39+44.1% | 5.13-28.4% | 7.16-4.4% | 7.50+31.6% | 5.70 |
| Tax | 5.21+148.9% | 2.09-56.8% | 4.85+322.3% | -2.18-734.7% | 0.34-84.3% | 2.18+134.5% | 0.93+177.1% | 0.34 |
| PROFIT | ||||||||
| PBT | 20.24+5408.1% | 0.37-98.6% | 26.83+13417.1% | 0.20-85.5% | 1.37-81.9% | 7.57+84.9% | 4.09+368.0% | 0.88 |
| Net Profit | 15.03+970.4% | -1.73-108.5% | 20.36+756.3% | 2.38+131.0% | 1.03-80.9% | 5.39+70.2% | 3.16+487.0% | 0.54 |
| KEY METRICS | ||||||||
| OPM % | 90.15%+79.26pp | 10.89%-58.45pp | 69.34%+76.48pp | -7.14%-31.60pp | 24.46%-30.70pp | 55.16%+34.00pp | 21.16%+38.28pp | -17.12% |
| NPM % | 62.46%+86.28pp | -23.82%-74.79pp | 50.97%+19.64pp | 31.33%+15.49pp | 15.84%-20.72pp | 36.56%+9.26pp | 27.30%+19.10pp | 8.20% |
| EPS | 0.34+750.0% | 0.04-91.5% | 0.47+840.0% | 0.05+150.0% | 0.02-83.3% | 0.12-83.3% | 0.72+188.0% | 0.25 |
Corporate Events
Board Meeting
The Board Meeting is scheduled to be held on Monday, Septemb…
BSE Filing ↗Board Meeting
The Board of Directors met on September 02, 2026. The meeti…
BSE Filing ↗Board Meeting
The Board of Directors considered and approved a proposal fo…
BSE Filing ↗Board Meeting
The meeting of the Board of Directors is scheduled to consid…
BSE Filing ↗Board Meeting
The Board took on record and confirmed the receipt of differ…
BSE Filing ↗Board Meeting
The Extra-Ordinary General Meeting (EGM) of the Members of S…
BSE Filing ↗Board Meeting
To consider and approve the Independent Directors Meeting.
BSE Filing ↗Board Meeting
Unaudited financial result for the Third Quarter ended on 31…
BSE Filing ↗Board Meeting
To consider and approve the Un-audited Financial Results of …
BSE Filing ↗Board Meeting
Consider and approve Shukra Pharmaceuticals
BSE Filing ↗Board Meeting
Consideration and approval of proposal for issuance of bonus…
BSE Filing ↗Board Meeting
Consider and approve unaudited financial result for the quar…
BSE Filing ↗Board Meeting
Consideration and approval of: 1. Unaudited financial result…
BSE Filing ↗